Alex Friedlaender
Alex Friedlaender
Verified email at
Cited by
Cited by
Cancer and COVID-19: Unmasking their ties
A Addeo, A Friedlaender
Cancer treatment reviews 88, 102041, 2020
How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
G Banna, A Curioni-Fontecedro, A Friedlaender, A Addeo
ESMO open 4, e000765, 2019
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
A Friedlaender, V Subbiah, A Russo, GL Banna, U Malapelle, C Rolfo, ...
Nature reviews Clinical oncology 19 (1), 51-69, 2022
TMB or not TMB as a biomarker: That is the question
A Addeo, A Friedlaender, GL Banna, GJ Weiss
Critical Reviews in Oncology/Hematology 163, 103374, 2021
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
A Friedlaender, A Drilon, GJ Weiss, GL Banna, A Addeo
Cancer treatment reviews 85, 101978, 2020
Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists
M Frigeri, P Meyer, C Banfi, R Giraud, AL Hachulla, D Spoerl, ...
Canadian Journal of Cardiology 34 (1), 92. e1-92. e3, 2018
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
M Chevallier, M Borgeaud, A Addeo, A Friedlaender
World Journal of Clinical Oncology 12 (4), 217, 2021
New emerging targets in cancer immunotherapy: the role of TIM3
A Friedlaender, A Addeo, G Banna
ESMO open 4, e000497, 2019
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab …
A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ...
Journal for immunotherapy of cancer 9 (4), 2021
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes
S De Talhouet, J Peron, A Vuilleumier, A Friedlaender, V Viassolo, ...
Scientific reports 10 (1), 7073, 2020
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
A Addeo, M Obeid, A Friedlaender
Journal for immunotherapy of cancer 8 (1), 2020
Next generation sequencing and genetic alterations in squamous cell lung carcinoma: where are we today?
A Friedlaender, G Banna, U Malapelle, P Pisapia, A Addeo
Frontiers in oncology 9, 166, 2019
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50%
A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ...
Cancer Immunology, Immunotherapy 69, 2209-2221, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation
A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ...
Journal for immunotherapy of cancer 8 (2), 2020
Immunotherapy in non-small cell lung cancer harbouring driver mutations
A Addeo, A Passaro, U Malapelle, GL Banna, V Subbiah, A Friedlaender
Cancer treatment reviews 96, 2021
Targeted therapies in early stage NSCLC: hype or hope?
A Friedlaender, A Addeo, A Russo, V Gregorc, D Cortinovis, CD Rolfo
International journal of molecular sciences 21 (17), 6329, 2020
Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes
A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ...
Clinical lung cancer 21 (6), 498-508. e2, 2020
The activity of immune checkpoint inhibition in KRAS mutated non-small cell lung cancer: a single centre experience
J Torralvo, A Friedlaender, V Achard, A Addeo
Cancer genomics & proteomics 16 (6), 577-582, 2019
A BRAF new world
D Frisone, A Friedlaender, U Malapelle, G Banna, A Addeo
Critical reviews in oncology/hematology 152, 103008, 2020
Poor-performance status assessment of patients with non-small cell lung cancer remains vague and blurred in the immunotherapy era
A Friedlaender, GL Banna, L Buffoni, A Addeo
Current oncology reports 21, 1-5, 2019
The system can't perform the operation now. Try again later.
Articles 1–20